Skip to content
Mankind and Bdr Pharma team up to launch the anti-Covid-19 pill Molulife

Mankind Pharma announced on Wednesday that it has partnered with BDR Pharmaceuticals to launch the oral anti-COVID-19 pill Molulife (Molnupiravir) in the country. The combination is a licensing agreement where production is handled by BDR Pharma and marketing, sales, promotion and distribution are handled by Mankind Pharma, the company said in a statement.

On Tuesday, the Drugs Controller General of India (DCGI) authorized the restricted use of the antiviral drug Molnupiravir in emergency situations for the treatment of COVID-19 in adult patients at high risk of disease progression. This launch further enhances the COVID-19 treatment portfolio in BDR’s product basket with the addition of generic Molnupiravir. We are delighted to be working with Mankind Pharma to take a step forward in the fight against the virus, ”said Raheel Shah, Director of Business Development at BDR Pharma.

Sanjay Koul, senior president of Mankind Pharma (sales and marketing), noted that a pill for COVID-19 would have to go miles to strengthen the defense against the battle of COVID-19. Humanity, with its motto “at the service of life”, will make Molulife available in every nook and cranny of the country, he added.

“The company is focused on providing a range of drugs for the management and treatment of COVID-19 in India,” Koul said.

(Edited by : Aditi Gautam)


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.